recombinant human thrombopoietin
Trials 51 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 10 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07595133 Comparator | Jun 2026 → Dec 2027 expected | infectious disease with sepsis | Shanghai 10th People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00006225 Background | Nov 1999 → Jan 2004 | breast cancer, leukemia, myelodysplastic/myeloproliferative disease, plasma cell neoplasm | Northwestern University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07400341 Comparator | Jan 2026 → Jan 2028 expected | aplastic anemia, myelodysplastic syndrome | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04324060 Comparator | Mar 2020 → Mar 2022 | myelodysplastic syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02241031 Comparator | Sep 2014 → Sep 2016 | thrombocytopenia | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06440824 Comparator | Jun 2024 → Jun 2025 | thrombocytopenia | Shandong University | Unknown | No outcome recorded |
| Phase 3 | NCT05669079 Background | Aug 2023 → Aug 2026 overdue | — | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03515096 Comparator | Jul 2018 → Aug 2021 | disease related to hematopoietic stem cell transplant, thrombocytopenia | Shenzhen Second People's Hospital | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01379391 Comparator | Jun 2010 → Sep 2015 | disease related to hematopoietic stem cell transplant, thrombocytopenia | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00038012 Background | Jul 1999 → Jun 2004 | female reproductive system neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 64 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human thrombopoietin | “To explore the early intervention timing of recombinant human thrombopoietin (rhTPO) for cancer treatment-induced thrombocytopenia (CTIT) in cervical squamous cell carcinoma...” NCT07649395 ↗37“A Randomized Phase II Study of Recombinant Human Thrombopoietin (Rh-TPO) and Recombinant Human Interleukin-11 (rhIL-11) for Recurrent Colorectal Cancer (CRC) Patients With...” NCT03823079 ↗ “Recombinant human thrombopoietin (rhTPO) is a glycoprotein molecule modified by full-length glycosylation and is of a similar pharmacological effect with endogenous...” NCT03515096 ↗ “Recombinant human thrombopoietin (rhTPO) is a full-length glycosylated-TPO produced by Chinese hamster ovary cells, which showed its effectiveness in ITP in a variety of studies.” NCT04516837 ↗ “The aim of this study was to determine the safety and efficacy of recombinant human thrombopoietin (rhTPO) for the management of immune thrombocytopenia (ITP) during pregnancy.” PMID 28630121 ↗ Jun 2017 “Recombinant human thrombopoietin (rhTPO) is also a kind of a TPO receptor agonists which is highly specific platelet stimulating factor.” NCT04324060 ↗ “Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China” NCT02707497 ↗ “subcutaneous injection of recombinant human thrombopoietin (rhTPO) 15000U once a week during the radiotherapy.” NCT05944809 ↗ “Recombinant human thrombopoietin (rhTPO), a full-length glycated TPO, is a recombinant form of c-Mpl ligand” NCT03771378 ↗ “Recombinant human thrombopoietin (rhTPO) is approved for thrombocytopenia after solid tumor chemotherapy” NCT04168138 ↗ “recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA)” NCT07653581 ↗ “rhTPO（Recombinant Human Thrombopoietin，TPIAO®” NCT02094248 ↗ “recombinant human thrombopoietin (rhTPO)” NCT05382390 ↗ “recombinant human thrombopoietin (rhTPO)” NCT05258799 ↗ “Recombinant Human Thrombopoietin” NCT01805648 ↗ |
| Known as | C-mpl ligand | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802180 ↗ |
| Known as | Megakaryocyte stimulating factor | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802180 ↗ |
| Known as | Megapoietin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802180 ↗ |
| Known as | Recombinant Human TPO | “Recombinant Human TPO” NCT01805648 ↗ |
| Known as | rhTPO | “A Randomized Phase II Study of Recombinant Human Thrombopoietin (Rh-TPO) and Recombinant Human Interleukin-11 (rhIL-11) for Recurrent Colorectal Cancer (CRC) Patients With...” NCT03823079 ↗44“Recombinant human thrombopoietin (rhTPO) is a glycoprotein molecule modified by full-length glycosylation and is of a similar pharmacological effect with endogenous...” NCT03515096 ↗ “This study aimed to evaluate the role of recombinant human thrombopoietin (rhTPO) before mobilization chemotherapy in facilitating leukapheresis in patients with lymphoma.” PMID 34505019 ↗ Jun 2021 “Recombinant human thrombopoietin (rhTPO), a full-length and glycosylated TPO with a molecular weight of 90 000 Daltons developed by 3SBIO (Shenyang, China)” NCT05634824 ↗ “rhTPO(recombinant human thrombopoietin) is given on the second, 4th and 9th day of the chemotherapy cycle in a dosage of 15000U once subcutaneously.” NCT01319669 ↗ “Preclinical studies and studies in adults have shown recombinant human thrombopoietin (rhTPO) to be effective in stimulating platelet production.” NCT00187109 ↗ “different recombinant human thrombopoietin (rhTPO) regimens” NCT04089267 ↗ “Recombinant human thrombopoietin for injection (rhTPO)” NCT06630494 ↗ “rhTPO（Recombinant Human Thrombopoietin，TPIAO®” NCT02094248 ↗ “Recombinant Human Thrombopoietin (rHTPO)” NCT01379391 ↗ “rhTPO(Recombinant human thrombopoietin)” NCT05350956 ↗ “Recombinant Human Thrombopoietin（rhTPO）” NCT06955858 ↗ “Recombinant Human Thrombopoietin（rhTPO）” NCT07476846 ↗ “The dose of rhTPO is 15,000 U per day.” NCT05217719 ↗ |
| Known as | rHuTPO | “Recombinant human thrombopoietin (rHuTPO) is a fully modified recombinant human thrombopoietin accurately expressed in mammalian cells.” NCT01379391 ↗ |
| Known as | Thrombopoietin | “Administer recombinant human thrombopoietin therapy. Thrombopoietin injection (specification: 15000 U/mL) is administered subcutaneously” NCT07595133 ↗ |
| Known as | TPIAO | “Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China” NCT01379391 ↗2“Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China” NCT02707497 ↗ “rhTPO（Recombinant Human Thrombopoietin，TPIAO®” NCT02094248 ↗ |
| Known as | TPIAOTM | “Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration)” NCT01506414 ↗ |
| Known as | TPO | “Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.” NCT02241031 ↗ |
| Action | Activate | “TPO is a specific cytokine of megakaryocyte, which can promote the proliferation and maturation of macronuclear progenitor cells by binding to the receptor c-mpl.” NCT03515096 ↗ |
| Modality | Protein / enzyme biologic | “Biological: recombinant human thrombopoietin” NCT00003597 ↗ |
| Route | Intravenous | “recombinant human thrombopoietin IV on days 4, 6, 8, 10, and 12” NCT00003597 ↗ |